Trevi Therapeutics (TRVI) Total Current Liabilities (2018 - 2026)

Trevi Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 3.63% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 3.63% increase from a year earlier, with the FY2025 full-year figure at $9.7 million, down 7.23% from the prior year.
• Total Current Liabilities slipped to $7.1 million in Q1 2026 per TRVI's latest filing, from $9.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $15.4 million in Q2 2022 and bottomed at $4.7 million in Q2 2023.
• The 5-year median for Total Current Liabilities is $9.1 million (2024), against an average of $9.3 million.
• Across the five-year window, Total Current Liabilities soared 141.05% in 2022 and slumped 69.47% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $13.4 million in 2022, then sank by 56.54% to $5.8 million in 2023, then jumped by 80.44% to $10.5 million in 2024, then retreated by 7.23% to $9.7 million in 2025, then slipped by 27.02% to $7.1 million in 2026.
• Per Business Quant, the three latest TRVI Total Current Liabilities figures stand at $7.1 million (Q1 2026), $9.7 million (Q4 2025), and $9.0 million (Q3 2025).